Biotie Therapies - Notice to convene extr.general meeting

Invitation to the Extraordinary General Meeting of Biotie Therapies Corp.

BIOTIE THERAPIES CORP.   STOCK EXCHANGE RELEASE 28 September 2009 at
9.00 a.m.


Invitation to the Extraordinary General Meeting of Biotie Therapies
Corp.

The Board of Directors of Biotie Therapies Corp. has resolved to call
for an Extraordinary General Meeting of shareholders to elect a new
member, Dr Peter Fellner, to the Board of Directors, and, due to the
recent amendment to the Finnish Companies Act, to amend the articles
of association accordingly. Furthermore, the General Meeting shall
decide on a proposed amendment of the current Board authorisation to
issue new shares to provide the Company with means to act swiftly in
the current volatile market conditions, although there are no
immediate plans to use the increased authorisation.

Notice is given to the shareholders of Biotie Therapies Corp. to the
Extraordinary General Meeting to be held on 29 October 2009 at 9 a.m.
in an auditorium at the premises of PharmaCity, address Itäinen
Pitkäkatu 4 B, Turku, Finland. The reception of shareholders who have
registered for the meeting and the distribution of voting tickets
will commence at 8.30 a.m.

A. MATTERS ON THE AGENDA OF THE EXTRAORDINARY GENERAL MEETING

At the Extraordinary General Meeting, the following matters will be
considered:

1. Opening of the meeting

2. Calling the meeting to order

3. Election of persons to confirm the minutes and to supervise the
counting of votes

4. Recording the legality of the meeting

5. Recording the attendance at the meeting and adoption of the list
of votes

6. Resolution on the number of members of the Board of Directors

The Board of Directors proposes on the basis of the recommendation of
the Nomination and Remuneration Committee that the number of members
of the Board of Directors would be eight (8).

7. Election of members of the Board of Directors

The Board of Directors proposes on the basis of the recommendation of
the Nomination and Remuneration Committee that Dr. Peter Fellner
would be elected as a new member of the Board of Directors for the
term expiring at the end of the following Annual General Meeting.
Peter Fellner, 65, currently serves as Chairman of Consort Medical
Plc, Chairman of Vernalis Plc and Chairman of Astex Therapeutics Ltd.
Previously he served as CEO of Celltech Group plc from 1990 to 2003,
and then as its Chairman until 2004. Prior to this he was CEO of
Roche UK from 1986 to 1990. He has also served as a director of
several other public companies.

8. The Board of Directors' proposal on amendment to the Articles of
Association

The Board of Directors proposes to the Extraordinary General Meeting
that due to the amendment to the Finnish Companies Act the
Extraordinary General Meeting shall amend the method and minimum
period for publishing the summons to the meetings in the Article 10
of the company's Articles of Association. After the amendment the
Article 10 shall be as follows:"10 § Summons to the meetings
The shareholders of the company are summoned to the shareholders'
meeting by publishing the summons on the company's website. The
summons shall be published not earlier than two (2) months before the
last registration date mentioned in the summons and not later than
three (3) weeks prior to the date of the meeting. In addition, the
Board of Directors shall publish a summary notice of the
shareholders' meeting in one or more national daily newspaper, or by
sending the notice of the shareholders' meeting as a registered
letter or other verifiable way to the shareholders' address, which is
registered in the share register."

9. Authorizing the Board of Directors to decide on the issuance of
shares as well as the issuance of options and other special rights
entitling to shares

The Board of Directors proposes that the Extraordinary General
Meeting would authorise the Board of Directors to resolve on one or
more issues which contains the right to issue new shares or dispose
of the shares in the possession of the company and to issue options
or other specific rights to the shares pursuant to chapter 10 of the
Companies Act. The authorisation would consist of up to 72,000,000
shares in the aggregate.

The authorisation would not exclude the Board of Directors' right to
decide on a directed issue. The authorisation is proposed to be used
for material arrangements from the company's point of view, such as
financing or implementing business arrangements or investments or for
other such purposes determined by the Board of Directors in which
case a weighty financial reason for issuing shares, options or other
specific rights and possibly directing a share issue would exist. The
authorisation could not, however, be used to create new share-based
incentive schemes.

The Board of Directors would be authorised to resolve on all other
terms and conditions of a share issue, options and other specific
share entitlements as referred to in chapter 10 of the Companies Act,
including the payment period, determination grounds for the
subscription price and subscription price or allocation of shares,
option rights or specific rights free of charge or that the
subscription price may be paid besides in cash also by other assets
either partially or entirely.

The authorisation would be effective until 30 June 2010. The Board of
Directors proposes that the authorisation shall supersede earlier
authorisations.

10. Closing of the meeting

B. DOCUMENTS OF THE EXTRAORDINARY GENERAL MEETING

The proposals of the Board of Directors relating to the agenda of the
Extraordinary General Meeting as well as this notice are available on
Biotie Therapies Corp.'s website at www.biotie.com no later than 8
October 2009. The proposals of the Board of Directors are also
available at the meeting. Copies of these documents and of this
notice will be sent to shareholders upon request. The minutes of the
meeting will be available on the above-mentioned website as from 12
November 2009.

C. INSTRUCTIONS FOR THE PARTICIPANTS IN THE EXTRAORDINARY GENERAL
MEETING

1. The right to participate and registration

Each shareholder, who is registered on the record date of the
meeting, 19 October 2009, in the shareholders' register of the
company held by Euroclear Finland Ltd, has the right to participate
in the Extraordinary General Meeting. A shareholder, whose shares are
registered on his/her personal book-entry account, is registered in
the shareholders' register of the company.

A shareholder, who wants to participate in the Extraordinary General
Meeting, shall register for the meeting no later than 26 October 2009
at 4 p.m. Finnish time by giving a prior notice of participation.
Such notice can be given:

a) by e-mail virve.nurmi@biotie.com;
b) by telephone +358 2 274 8911; or
c) by regular mail to Biotie Therapies Corp. / Virve Nurmi,
Tykistökatu 6, FI-20520 Turku, Finland.

In connection with the registration, a shareholder shall notify
his/her name, personal identification number, address, telephone
number and the name of a possible assistant. The personal data given
to Biotie Therapies Corp. is used only in connection with the
Extraordinary General Meeting and with the processing of related
registrations.

Pursuant to chapter 5, section 25 of the Companies Act, a shareholder
who is present at the Extraordinary General Meeting has the right to
request information with respect to the matters to be considered at
the meeting.

2. Proxy representative and powers of attorney

A shareholder may participate in the Extraordinary General Meeting
and exercise his/her rights at the meeting by way of proxy
representation. A proxy representative shall produce a dated proxy
document or otherwise in a reliable manner demonstrate his/her right
to represent the shareholder at the Extraordinary General Meeting.

A shareholder may also exercise his/her rights at the meeting by way
of several proxies, representing the shareholder with shares on
different book-entry accounts. If the shareholder participates in the
meeting by several proxies, the shares with which each proxy
representative represents the shareholder shall be notified in
connection with the registration.

Possible proxy documents should be delivered in originals to the
company before the last date for registration.

3. Holders of nominee registered shares

A holder of nominee registered shares may be temporarily entered into
the shareholders' register of the company for the purposes of
participating in the Extraordinary General Meeting, if the
shareholder is, based on his/her shareholding, entitled to be
registered in the shareholders' register on the record date of the
meeting, 19 October 2009. The notice regarding the temporary entry
shall be given at latest on 23 October 2009. If a holder of nominee
registered shares is temporarily entered into the shareholders'
register of the company, the entry is taken also as a registration
for participating in the meeting. A holder of nominee registered
shares is advised to request necessary instructions regarding the
registration in the shareholder's register of the company, the
issuing of proxy documents and registration for the Extraordinary
General Meeting from his/her custodian bank.

4. Other information

On the date of this notice to the Extraordinary General Meeting, 28
September 2009, the total number of shares and votes in Biotie
Therapies Corp. is 144,320,560.

In Turku, 28 September 2009

Biotie Therapies Corp.
Board of Directors

For further information, please contact:
Timo Veromaa, President and CEO, Biotie Therapies Corp.
tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com
www.biotie.com

DISTRIBUTION:

NASDAQ OMX Helsinki Ltd
Main Media